The appointment gives the Chinese private equity player access to the network and knowledge of the one-time candidate for the top job at GSK.

The appointment puts the former FDA commissioner in a position to work with Immunocore, Poseida Therapeutics and the fund's other cancer biotechs.

The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.

Allena arrives on Wall Street armed with data from two phase 2 flops and a pivotal trial design that has so far failed to win over the FDA.

PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.

The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.

A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.

Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of cancer drugs that target sugar-sensing molecules.

Immatics turned to existing investors and new partner Amgen to put together the round, which brings its total raised to date up toward €200 million.

Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe.

Venture Capital